[{"address1": "11711 North Meridian Street", "address2": "Suite 300", "city": "Carmel", "state": "IN", "zip": "46032", "country": "United States", "phone": "317 659 0200", "website": "https://mbxbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.", "fullTimeEmployees": 43, "companyOfficers": [{"maxAge": 1, "name": "Mr. Peter Kent Hawryluk MBA", "age": 55, "title": "CEO, President & Director", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 788300, "exercisedValue": 0, "unexercisedValue": 12366896}, {"maxAge": 1, "name": "Mr. Richard B. Bartram CPA", "age": 43, "title": "Chief Financial Officer", "yearBorn": 1981, "fiscalYear": 2024, "totalPay": 642001, "exercisedValue": 0, "unexercisedValue": 3084960}, {"maxAge": 1, "name": "Dr. Salomon  Azoulay M.D.", "age": 66, "title": "Chief Medical Officer", "yearBorn": 1958, "fiscalYear": 2024, "totalPay": 520512, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matt  Gambino", "title": "Vice President of Marketing", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Michelle  Graham", "age": 57, "title": "Chief Human Resources Officer", "yearBorn": 1967, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael A. Dorato DABT, Ph.D.", "title": "Sr. Vice President of Discovery & Non-Clinical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Chatan  Charan Ph.D.", "title": "Senior VP of Pharmaceutical Development & Chemistry, Manufacturing and Controls", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark  Hope", "title": "Senior Vice President of Regulatory & Quality", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Andreas  Moraitis M.D.", "title": "Senior Vice President of Clinical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 9, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1756684800, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 10.07, "open": 10.01, "dayLow": 9.67, "dayHigh": 10.28, "regularMarketPreviousClose": 10.07, "regularMarketOpen": 10.01, "regularMarketDayLow": 9.67, "regularMarketDayHigh": 10.28, "payoutRatio": 0.0, "forwardPE": -4.291846, "volume": 533685, "regularMarketVolume": 533685, "averageVolume": 441955, "averageVolume10days": 561040, "averageDailyVolume10Day": 561040, "bid": 7.23, "ask": 12.51, "bidSize": 2, "askSize": 2, "marketCap": 335938624, "fiftyTwoWeekLow": 4.807, "fiftyTwoWeekHigh": 27.5, "fiftyDayAverage": 12.7661, "twoHundredDayAverage": 12.090475, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 111682656, "profitMargins": 0.0, "floatShares": 14609972, "sharesOutstanding": 33593866, "sharesShort": 3843321, "sharesShortPriorMonth": 5342249, "sharesShortPreviousMonthDate": 1753920000, "dateShortInterest": 1756425600, "sharesPercentSharesOut": 0.1144, "heldPercentInsiders": 0.030989999, "heldPercentInstitutions": 1.09784, "shortRatio": 9.76, "shortPercentOfFloat": 0.2289, "impliedSharesOutstanding": 33593866, "bookValue": 6.526, "priceToBook": 1.5323322, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -77019000, "trailingEps": -6.24, "forwardEps": -2.33, "enterpriseToEbitda": -1.294, "52WeekChange": -0.5509654, "SandP52WeekChange": 0.1653893, "quoteType": "EQUITY", "currentPrice": 10.0, "targetHighPrice": 44.0, "targetLowPrice": 30.0, "targetMeanPrice": 37.71429, "targetMedianPrice": 38.0, "recommendationMean": 1.28571, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 7, "totalCash": 224906000, "totalCashPerShare": 6.695, "ebitda": -86285000, "totalDebt": 650000, "quickRatio": 19.203, "currentRatio": 19.496, "debtToEquity": 0.296, "returnOnAssets": -0.36751, "returnOnEquity": -0.56278, "freeCashflow": -45419500, "operatingCashflow": -70813000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "MBX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "MBX Biosciences, Inc.", "longName": "MBX Biosciences, Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1726234200000, "postMarketChangePercent": 36.3, "postMarketPrice": 13.63, "postMarketChange": 3.63, "regularMarketChange": -0.0699997, "regularMarketDayRange": "9.67 - 10.28", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 441955, "fiftyTwoWeekLowChange": 5.193, "fiftyTwoWeekLowChangePercent": 1.0802995, "fiftyTwoWeekRange": "4.807 - 27.5", "fiftyTwoWeekHighChange": -17.5, "fiftyTwoWeekHighChangePercent": -0.6363636, "fiftyTwoWeekChangePercent": -55.096542, "earningsTimestamp": 1754539200, "earningsTimestampStart": 1762432200, "earningsTimestampEnd": 1762432200, "earningsCallTimestampStart": 1754564400, "earningsCallTimestampEnd": 1754564400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -6.24, "epsForward": -2.33, "epsCurrentYear": -2.70051, "priceEpsCurrentYear": -3.7030041, "exchange": "NMS", "messageBoardId": "finmb_613097171", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -0.695131, "regularMarketPrice": 10.0, "fiftyDayAverageChange": -2.7661, "fiftyDayAverageChangePercent": -0.21667542, "twoHundredDayAverageChange": -2.090475, "twoHundredDayAverageChangePercent": -0.17290264, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2024-09-13", "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1758326396, "regularMarketTime": 1758312002, "marketState": "CLOSED", "displayName": "MBX Biosciences", "trailingPegRatio": null, "__fetch_time": "2025-09-20"}]